---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022721"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2026-05-13T20:10:20+00:00"
generated_at: "2026-05-13T22:06:12.444579+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# iMDx reports Q1 net loss $4.3M; signs first GALACTIC trial site, advances FDA submission

## Summary
- Q1 revenue ~$32K, gross profit $15K; net loss $4.3M ($0.12/share); non-GAAP net loss $9.6M ($0.28/share).
- Signed first clinical trial agreement for GALACTIC registry with a top-10 U.S. kidney transplant center.
- Non-GAAP operating expenses $4.4M including $5.9M non-cash gain; R&D down 15% sequentially.
- Expect FDA marketing authorization for GraftAssureDx later 2026; productive FDA dialogue ongoing.
- Small RUO orders from Switzerland and pending from Southeast Asia; first U.S. orders anticipated later this year.

## SEC filing metadata
- accession: 0001493152-26-022721
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2026-05-13T20:10:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315226022721/0001493152-26-022721-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315226022721/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022721
- JSON: https://secwatch.observer/filing/0001493152-26-022721.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022721.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.